Pacific Biosciences of California, Inc.

NasdaqGS:PACB Rapport sur les actions

Capitalisation boursière : US$436.0m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Pacific Biosciences of California Bilan de santé

Santé financière contrôle des critères 2/6

Pacific Biosciences of California possède un total de capitaux propres de $492.7M et une dette totale de $892.8M, ce qui porte son ratio d'endettement à 181.2%. Son actif total et son passif total sont $1.5B et de $1.0B.

Informations clés

181.2%

Ratio d'endettement

US$892.84m

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$509.80m
Fonds propresUS$492.70m
Total du passifUS$1.02b
Total des actifsUS$1.51b

Mises à jour récentes de la santé financière

Recent updates

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook

Aug 08
Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de PACB ( $628.1M ) dépassent ses passifs à court terme ( $78.4M ).

Passif à long terme: Les actifs à court terme de PACB ( $628.1M ) ne couvrent pas ses passifs à long terme ( $938.4M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de PACB ( 77.7% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de PACB est passé de 20.1% à 181.2% au cours des 5 dernières années.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: PACB dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: Données insuffisantes pour déterminer si PACB dispose de suffisamment de piste de trésorerie si son flux de trésorerie disponible continue de croître ou de diminuer en fonction des taux historiques.


Découvrir des entreprises saines